Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
Breast CancerMale Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

vorinostat

Given orally

DRUG

trastuzumab

Given IV

Trial Locations (25)

10011

Saint Vincent's Hospital and Medical Center of New York, New York

10461

Albert Einstein College of Medicine, The Bronx

35294

University of Alabama at Birmingham, Birmingham

50307

Mercy Capitol, Des Moines

50309

Iowa Methodist Medical Center, Des Moines

Iowa Oncology Research Association CCOP, Des Moines

Medical Oncology and Hematology Associates-Des Moines, Des Moines

50314

Medical Oncology and Hematology Associates, Des Moines

Mercy Medical Center - Des Moines, Des Moines

50316

Iowa Lutheran Hospital, Des Moines

51101

Siouxland Hematology Oncology Associates, Sioux City

51104

Mercy Medical Center-Sioux City, Sioux City

Saint Luke's Regional Medical Center, Sioux City

55101

Regions Hospital, Saint Paul

55102

Saint Joseph's Hospital - Healtheast, Saint Paul

55109

Saint John's Hospital - Healtheast, Maplewood

55125

Woodwinds Health Campus, Woodbury

55350

Hutchinson Area Health Care, Hutchinson

55355

Meeker County Memorial Hospital, Litchfield

55379

Saint Francis Regional Medical Center, Shakopee

55407

Virginia Piper Cancer Institute, Minneapolis

55415

Hennepin County Medical Center, Minneapolis

21287-8936

Johns Hopkins University, Baltimore

02215

Eastern Cooperative Oncology Group, Boston

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00258349 - Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | Biotech Hunter | Biotech Hunter